• “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>新品动态>Boston Scientific 获准销售PrecISion Plus脊髓膜拟器系统的分离器

    时时彩 庄闲: Boston Scientific 获准销售PrecISion Plus脊髓膜拟器系统的分离器

    Boston Scientific2010年6月25日 10:32 点击:2553

    时时彩网络平台 www.qlgr.net
    美国波士顿科学Boston Scientific 美国食品药品监督管理局(FDA,U.S. Food and Drug Administration)

    Boston Scientific 获准销售PrecISion Plus脊髓膜拟器系统的分离器

     

    Boston Scientific Announces FDA Approval and Launch of Lead Splitters for the Precision Plus™ Spinal Cord Stimulator System
    Two new splitters allow multi-site placement of up to four spinal cord stimulation leads

    Jun 24, 2010

    NATICK, Mass., June 24 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration approval and launch of two spinal cord stimulation (SCS) lead splitters for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk, back and/or limbs.  The W4 and D4 splitters each enable multi-site placement of up to four leads, which are designed to deliver electrical pulses to the spinal cord that mask pain signals to the brain.  The products will be introduced at the 12th annual meeting of the American Society of Interventional Pain Physicians (ASIPP), June 26 – 30 in Arlington, Virginia.

    The new splitters offer a broader range of lead configurations and are designed to provide physicians more treatment options for their chronic pain patients.  

    "Spinal cord stimulation is an important treatment option for chronic pain," said Giancarlo Barolat, M.D., Medical Director of Barolat Neuroscience in Denver.  "Boston Scientific's lead splitters give pain management physicians more choices to help optimize pain relief when using the Precision Plus System."  

    "Our goal is to design products that provide lasting pain relief for patients," said Michael Onuscheck, Senior Vice President and President of Boston Scientific's Neuromodulation Division.  "We are pleased to introduce this expanded line of splitters for multi-site SCS lead placement."  

    Pain is the most common reason Americans seek medical treatment, and an estimated 26 million Americans experience frequent back pain.  Many chronic pain patients have found that SCS helps them manage their pain and live better lives.  

    Boston Scientific will present its full line of Neuromodulation products at booth #22/43 at the ASIPP annual meeting.

    About Boston Scientific Neuromodulation

    Boston Scientific Neuromodulation is an innovation leader in implantable pain management technology.  The Precision Plus™ Spinal Cord Stimulator System, powered by SmoothWave™ Technology, uses pulses of electricity delivered directly along nerve fibers through the spinal cord to mask pain signals to the brain.  Through its investments in technology, clinical science and world-class service, Boston Scientific Neuromodulation is committed to Making life smoother™ for physicians and patients.  For more information on Precision Plus technology, visit //www.ControlYourPain.com.

    About Boston Scientific

    Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

    Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:

    Paul Donovan

     

     

    508-650-8541 (office)

     

     

    508-667-5165 (mobile)

     

     

    Media Relations

     

     

    Boston Scientific Corporation

     

     

     
     

     

    Larry Neumann

     

     

    508-650-8696 (office)

     

     

    Investor Relations

     

     

    Boston Scientific Corporation

     
       


     

    SOURCE Boston Scientific Corporation

    (来源: Boston Scientific )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 排列5预测专家最准确 年红姐特码诗 三人斗地主 246好彩天天免费资枓大全 单机斗地主免费版2018 2019特别好码八句诗 甘肃十一选五前三 三地和值走势图 广西福彩双采現场开奖结果 快乐扑克3顺子规律 赌场如何换筹码 新疆25选7什么时候开奖时间 今日湖北快三走势图专家预测 重庆快乐十分限号规则 没运气中彩票大奖